JP2013507446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507446A5 JP2013507446A5 JP2012534288A JP2012534288A JP2013507446A5 JP 2013507446 A5 JP2013507446 A5 JP 2013507446A5 JP 2012534288 A JP2012534288 A JP 2012534288A JP 2012534288 A JP2012534288 A JP 2012534288A JP 2013507446 A5 JP2013507446 A5 JP 2013507446A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 135
- 125000003118 aryl group Chemical group 0.000 claims 130
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 90
- 229910052739 hydrogen Inorganic materials 0.000 claims 73
- 239000001257 hydrogen Substances 0.000 claims 73
- 125000000217 alkyl group Chemical group 0.000 claims 69
- 125000000753 cycloalkyl group Chemical group 0.000 claims 69
- 125000000623 heterocyclic group Chemical group 0.000 claims 51
- 150000002431 hydrogen Chemical group 0.000 claims 50
- 229910052736 halogen Inorganic materials 0.000 claims 47
- 150000002367 halogens Chemical class 0.000 claims 41
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims 37
- 125000003545 alkoxy group Chemical group 0.000 claims 36
- 125000001424 substituent group Chemical group 0.000 claims 34
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000005843 halogen group Chemical group 0.000 claims 30
- 125000001153 fluoro group Chemical group F* 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 26
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 23
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 22
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 18
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 18
- 125000003107 substituted aryl group Chemical group 0.000 claims 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 8
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 8
- 101710150104 Sensory rhodopsin-1 Proteins 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 claims 2
- 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229940124108 Growth factor receptor agonist Drugs 0.000 claims 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 claims 1
- 102000027430 HGF receptors Human genes 0.000 claims 1
- 108091008603 HGF receptors Proteins 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 229940122474 Hepatocyte growth factor receptor agonist Drugs 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*(C)(C(N)=O)c1nnc(Nc2nnc(*(O)P=C)nn2)nn1 Chemical compound C*(C)(C(N)=O)c1nnc(Nc2nnc(*(O)P=C)nn2)nn1 0.000 description 5
- WHTKAPAWZRHEFP-UHFFFAOYSA-N C=[I]c(cc1)ccc1C(Nc(cc1)ccc1C(C(C=C1)=CCC1NC(c(cc1)ccc1F)=O)=O)=[U] Chemical compound C=[I]c(cc1)ccc1C(Nc(cc1)ccc1C(C(C=C1)=CCC1NC(c(cc1)ccc1F)=O)=O)=[U] WHTKAPAWZRHEFP-UHFFFAOYSA-N 0.000 description 1
- ZPCSMPJFGZYICP-UHFFFAOYSA-N CC(c1cc(C(Nc(cc2)ccc2C(c(cc2)ccc2[N](C)(C)C)=O)=O)ccc1)=[U] Chemical compound CC(c1cc(C(Nc(cc2)ccc2C(c(cc2)ccc2[N](C)(C)C)=O)=O)ccc1)=[U] ZPCSMPJFGZYICP-UHFFFAOYSA-N 0.000 description 1
- HBEAGIZSVJJESK-UHFFFAOYSA-M Cc(cc1)cc(C)c1C([N-]c(cc1)ccc1C(c(cc1)ccc1NC(c1c(C)cc(C)cc1)=O)=N)=O Chemical compound Cc(cc1)cc(C)c1C([N-]c(cc1)ccc1C(c(cc1)ccc1NC(c1c(C)cc(C)cc1)=O)=N)=O HBEAGIZSVJJESK-UHFFFAOYSA-M 0.000 description 1
- UWHGYVXFFUGPIL-UHFFFAOYSA-N Cc1cc(C(Nc(cc2)ccc2-c2nnc(-c(cc3)ccc3NC(c3cc(C)ccc3)=[U])[o]2)=O)ccc1 Chemical compound Cc1cc(C(Nc(cc2)ccc2-c2nnc(-c(cc3)ccc3NC(c3cc(C)ccc3)=[U])[o]2)=O)ccc1 UWHGYVXFFUGPIL-UHFFFAOYSA-N 0.000 description 1
- YHNAKSMBIBBBRQ-UHFFFAOYSA-N N=C(c(ccc(C(O)=O)c1)c1C(Nc(cc1)ccc1C(c(cc1)ccc1NC(c1cc(C(O)=O)ccc1C(O)=O)=O)=O)=O)O Chemical compound N=C(c(ccc(C(O)=O)c1)c1C(Nc(cc1)ccc1C(c(cc1)ccc1NC(c1cc(C(O)=O)ccc1C(O)=O)=O)=O)=O)O YHNAKSMBIBBBRQ-UHFFFAOYSA-N 0.000 description 1
- BYENYMZIPQBBOG-UHFFFAOYSA-N OC(CC1)CCN1c(cc1)ccc1C(Nc(cc1)ccc1Nc(cc1)ccc1NC(c1ccc2[nH]ccc2c1)=O)=O Chemical compound OC(CC1)CCN1c(cc1)ccc1C(Nc(cc1)ccc1Nc(cc1)ccc1NC(c1ccc2[nH]ccc2c1)=O)=O BYENYMZIPQBBOG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25125909P | 2009-10-13 | 2009-10-13 | |
| US61/251,259 | 2009-10-13 | ||
| PCT/US2010/052359 WO2011046954A1 (en) | 2009-10-13 | 2010-10-12 | Hematopoietic growth factor mimetic small molecule compounds and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015194455A Division JP6238942B2 (ja) | 2009-10-13 | 2015-09-30 | 造血成長因子模倣小分子化合物およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507446A JP2013507446A (ja) | 2013-03-04 |
| JP2013507446A5 true JP2013507446A5 (enExample) | 2013-11-28 |
| JP5819305B2 JP5819305B2 (ja) | 2015-11-24 |
Family
ID=43876487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534288A Active JP5819305B2 (ja) | 2009-10-13 | 2010-10-12 | 造血成長因子模倣小分子化合物およびそれらの使用 |
| JP2015194455A Active JP6238942B2 (ja) | 2009-10-13 | 2015-09-30 | 造血成長因子模倣小分子化合物およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015194455A Active JP6238942B2 (ja) | 2009-10-13 | 2015-09-30 | 造血成長因子模倣小分子化合物およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9144557B2 (enExample) |
| EP (1) | EP2488486B1 (enExample) |
| JP (2) | JP5819305B2 (enExample) |
| KR (1) | KR101804588B1 (enExample) |
| CN (1) | CN102656141B (enExample) |
| AU (1) | AU2010307006B2 (enExample) |
| CA (1) | CA2777565C (enExample) |
| DK (1) | DK2488486T3 (enExample) |
| ES (1) | ES2749504T3 (enExample) |
| PL (1) | PL2488486T3 (enExample) |
| PT (1) | PT2488486T (enExample) |
| WO (1) | WO2011046954A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| DK3366686T3 (da) | 2009-03-20 | 2020-11-23 | Metabasis Therapeutics Inc | Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf |
| SI2575968T1 (sl) | 2010-06-01 | 2016-06-30 | Summit Therapeutics Plc | Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile |
| WO2011151618A2 (en) * | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile-associated disease |
| CN103282034A (zh) * | 2010-11-18 | 2013-09-04 | 利亘制药公司 | 造血生长因子模拟物的用途 |
| WO2012167133A2 (en) * | 2011-06-01 | 2012-12-06 | The Regents Of The University Of California | Inhibitors of anandamide transport and their therapeutic uses |
| CA2844812C (en) | 2011-08-19 | 2019-10-22 | Daniele Piomelli | Meta-substituted biphenyl peripherally restricted faah inhibitors |
| IN2014MN02338A (enExample) * | 2012-05-31 | 2015-08-14 | Pharmascience Inc | |
| JP6243908B2 (ja) | 2012-08-23 | 2017-12-06 | アリオス バイオファーマ インク． | パラミクソウイルス感染症を治療するための化合物 |
| DK3054936T5 (da) | 2013-10-10 | 2024-03-18 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer |
| CA2931279A1 (en) * | 2013-11-25 | 2015-05-28 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
| US9732095B2 (en) | 2014-01-13 | 2017-08-15 | Aurigene Discovery Technologies Limited | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors |
| EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| SG11201608708WA (en) | 2014-05-15 | 2016-11-29 | Iteos Therapeutics | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
| CA2952188A1 (en) * | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
| EP3169683A4 (en) * | 2014-07-16 | 2017-11-22 | Novogen Ltd. | Functionalised and substituted indoles as anti-cancer agents |
| JP6675407B2 (ja) | 2014-10-10 | 2020-04-01 | プルモシデ リミテド | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 |
| JP6499306B2 (ja) * | 2014-10-24 | 2019-04-10 | ランドス バイオファーマ インコーポレイテッド | ランチオニンシンテターゼｃ様２系治療薬 |
| EP3233867B1 (en) | 2014-12-18 | 2018-10-17 | Pulmocide Limited | 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections |
| WO2016147144A1 (en) | 2015-03-17 | 2016-09-22 | Pfizer Inc. | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2016191667A2 (en) * | 2015-05-28 | 2016-12-01 | Ecolab Usa Inc. | Novel corrosion inhibitors |
| US10202694B2 (en) | 2015-05-28 | 2019-02-12 | Ecolab Usa Inc. | 2-substituted imidazole and benzimidazole corrosion inhibitors |
| WO2016204079A1 (ja) * | 2015-06-15 | 2016-12-22 | 日産化学工業株式会社 | 電荷輸送性ワニス及び有機エレクトロルミネッセンス素子 |
| CA2994917A1 (en) | 2015-08-10 | 2017-02-16 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| CN110234640B (zh) * | 2016-09-20 | 2023-04-07 | 利昂贝拉尔中心 | 作为抗癌剂的苯并咪唑衍生物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) * | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| CN110691589A (zh) | 2017-03-31 | 2020-01-14 | 奥列基因发现技术有限公司 | 用于治疗血液病的化合物和组合物 |
| FI3704108T3 (fi) | 2017-10-31 | 2024-05-23 | Curis Inc | Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon |
| KR102235476B1 (ko) | 2018-03-30 | 2021-04-01 | 주식회사 엘지화학 | 액정 배향제 조성물, 이를 이용한 액정 배향막의 제조 방법, 및 이를 이용한 액정 배향막 |
| KR20200059389A (ko) | 2018-11-21 | 2020-05-29 | 정예림 | 휴대용 탈취제 펜던트 |
| WO2021236717A1 (en) * | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| WO2022076975A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| CN116745267A (zh) * | 2020-12-11 | 2023-09-12 | 跨膜蛋白16A有限公司 | 用于治疗呼吸系统疾病的苯并咪唑衍生物 |
| CN114853679A (zh) * | 2021-02-04 | 2022-08-05 | 清药同创(北京)药物研发中心有限公司 | 一种苯并咪唑类enl蛋白抑制剂及其制备方法和用途 |
| IL307465A (en) | 2021-04-08 | 2023-12-01 | Curis Inc | Combined therapies for cancer treatment |
| EP4265246A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
| DE102022131737A1 (de) | 2022-11-30 | 2024-06-06 | Technische Universität München, Körperschaft des öffentlichen Rechts | Pyrrol-Verbindung und Verfahren zur Herstellung einer Pyrrol-Verbindung |
| CN120118037B (zh) * | 2023-12-07 | 2025-11-28 | 南华大学 | 一类含苯甲酸酯结构的苯并咪唑类化合物、制造方法及其用途 |
| CN119409969B (zh) * | 2024-09-11 | 2025-10-03 | 东华大学 | 一种苯并咪唑透明聚酰亚胺薄膜及其制备方法和应用 |
| US12391800B1 (en) * | 2025-03-18 | 2025-08-19 | Imam Mohammad Ibn Saud Islamic University | Tetraphenylethene-based polymers for supercapacitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2777855A (en) * | 1954-12-01 | 1957-01-15 | American Cyanamid Co | Amides of hydroxybenzotriazole carboxylic acids |
| US3245995A (en) * | 1964-03-09 | 1966-04-12 | Allied Chem | Bis-(6-oxo-6h-anthra-[9, 1-cd]-isothiazole-3-carboxamide) derivatives |
| GB1236282A (en) | 1968-07-15 | 1971-06-23 | Monsanto Co | Improvements in or relating to the pre-oxidation of thermally resistant aromatic polymers |
| DE2230121A1 (de) | 1972-06-21 | 1974-01-17 | Basf Ag | Polyamidimide und verfahren zu ihrer herstellung |
| US5296591A (en) | 1990-12-31 | 1994-03-22 | Fujisawa Pharmaceutical Co., Ltd. | Trifluoromethylketone derivatives, processes for preparation thereof and use thereof |
| US6191146B1 (en) * | 1995-11-13 | 2001-02-20 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| JP3231792B2 (ja) | 1996-10-14 | 2001-11-26 | 株式会社上野製薬応用研究所 | ビス（アミノカルボニルナフトール）誘導体 |
| ES2216579T3 (es) | 1998-10-09 | 2004-10-16 | Janssen Pharmaceutica N.V. | Derivados de 4,5-dihidro-isoxazol y su uso farmaceutico. |
| GB9908828D0 (en) * | 1999-04-16 | 1999-06-16 | Univ Reading The | Compounds |
| CN1252121C (zh) | 1999-05-07 | 2006-04-19 | 株式会社上野制药应用研究所 | 液晶聚合物 |
| AU2001227084A1 (en) * | 2000-01-25 | 2001-08-07 | Japan Tobacco Inc. | N-arylhydrazide compounds and use thereof as drugs |
| AU2001260661A1 (en) * | 2000-05-30 | 2001-12-11 | Chugai Seiyaku Kabushiki Kaisha | Compounds exhibiting thrombopoietin-like activities |
| GB0126036D0 (en) | 2001-10-30 | 2001-12-19 | Amedis Pharm Ltd | Silicon compounds |
| EP1477475A1 (en) * | 2003-05-16 | 2004-11-17 | Procorde GmbH | Compounds for use as a medicine increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| EA010911B1 (ru) | 2003-09-11 | 2008-12-30 | Тиботек Фармасьютикалз Лтд. | Ингибиторы проникновения вируса вич |
| BRPI0514150A (pt) | 2004-08-06 | 2007-11-27 | Otsuka Pharma Co Ltd | composto aromático ou um sal do mesmo, método para produzir o mesmo, e, composição farmacêutica para tratar a fibrose |
| MX2007011500A (es) | 2005-03-16 | 2007-11-21 | Targegen Inc | Compuestos pirimidina y metodos de uso. |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| CA2645434A1 (en) * | 2006-03-20 | 2007-09-27 | Synta Pharmaceutical Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| WO2007112093A2 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| US8030487B2 (en) * | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
| EA201000422A1 (ru) * | 2007-09-04 | 2010-08-30 | Биолипокс Аб | Бисароматические соединения, применимые при лечении воспаления |
| CN101215379A (zh) | 2008-01-04 | 2008-07-09 | 四川大学 | 聚芳硫醚酰胺类聚合物及其制备方法 |
| FR2926297B1 (fr) * | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| ES2524883T3 (es) | 2008-03-18 | 2014-12-15 | Merck Sharp & Dohme Corp. | 4-Hidroxipirimidina-5-carboxamidas sustituidas |
| WO2009155362A1 (en) * | 2008-06-19 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Small molecule hematopoietic growth factor mimetic compounds and their uses |
| KR100994687B1 (ko) * | 2008-10-30 | 2010-11-17 | 한국과학기술연구원 | 신규 피롤로[3,2-ｂ]피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 흑색종 예방 또는 치료용 약학적 조성물 |
| CA2743723A1 (en) * | 2008-11-19 | 2010-05-27 | Pauline C. Ting | Inhibitors of diacylglycerol acyltransferase |
-
2010
- 2010-10-12 CN CN201080055349.5A patent/CN102656141B/zh active Active
- 2010-10-12 CA CA2777565A patent/CA2777565C/en active Active
- 2010-10-12 KR KR1020127012390A patent/KR101804588B1/ko active Active
- 2010-10-12 WO PCT/US2010/052359 patent/WO2011046954A1/en not_active Ceased
- 2010-10-12 JP JP2012534288A patent/JP5819305B2/ja active Active
- 2010-10-12 ES ES10823959T patent/ES2749504T3/es active Active
- 2010-10-12 PT PT108239591T patent/PT2488486T/pt unknown
- 2010-10-12 AU AU2010307006A patent/AU2010307006B2/en active Active
- 2010-10-12 US US13/501,622 patent/US9144557B2/en not_active Expired - Fee Related
- 2010-10-12 PL PL10823959T patent/PL2488486T3/pl unknown
- 2010-10-12 DK DK10823959T patent/DK2488486T3/da active
- 2010-10-12 EP EP10823959.1A patent/EP2488486B1/en active Active
-
2015
- 2015-05-15 US US14/713,930 patent/US9622991B2/en active Active
- 2015-09-30 JP JP2015194455A patent/JP6238942B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507446A5 (enExample) | ||
| ES2791186T3 (es) | Triazoles como inhibidores de receptores NR2B | |
| JP2014502266A5 (enExample) | ||
| KR102534266B1 (ko) | 헤테로환형 유도체 및 이의 용도 | |
| JP2009530424A5 (enExample) | ||
| WO2021068898A1 (zh) | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 | |
| RU2018103907A (ru) | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ | |
| ES2798424T3 (es) | Compuestos de triazolopiridina y usos de estos | |
| RU2012136451A (ru) | Композиции и способы улучшения активности протеасомы | |
| JP2015522650A5 (enExample) | ||
| AU2017260305B2 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| AU2025267332A1 (en) | Psychotropic agents and uses thereof | |
| JP2013514980A5 (enExample) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2017501237A5 (enExample) | ||
| JP2017536416A5 (enExample) | ||
| JP2006523192A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| RU2013125326A (ru) | Гетероциклические соединения в качестве зондов для визуализации tau-патологии | |
| JP2014500296A5 (enExample) | ||
| ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
| RU2018103332A (ru) | Пиримидиновое соединение с конденсированными кольцами, его промежуточное соединение, способ получения, композиция и применение | |
| ES2701087T3 (es) | Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis |